Danaher Co. (NYSE:DHR) Shares Sold by Trust Co of the South

Trust Co of the South decreased its stake in shares of Danaher Co. (NYSE:DHR) by 15.8% during the fourth quarter, HoldingsChannel reports. The firm owned 1,127 shares of the conglomerate’s stock after selling 212 shares during the quarter. Trust Co of the South’s holdings in Danaher were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher during the third quarter worth about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in Danaher in the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DHR. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. UBS Group lowered their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Raymond James lowered their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $287.05.

Danaher Price Performance

NYSE:DHR traded down $0.84 during trading hours on Thursday, hitting $228.71. 1,909,612 shares of the stock were exchanged, compared to its average volume of 2,806,454. The firm’s fifty day moving average price is $236.94 and its 200 day moving average price is $254.65. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The company has a market cap of $165.19 billion, a P/E ratio of 43.65, a P/E/G ratio of 4.33 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business posted $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.